Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 9/20 | 0.63 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | MYC | P01106 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5922313 | 0.93 | CHRNA7 (0.56) | NOTUMCHRNA7ALDH1A1MYCNR4A1 | |
| SCHEMBL5922340 | 0.90 | CHRNA7 (0.54) | NOTUMCHRNA7ALDH1A1CNR1CNR2 | |
| SCHEMBL4474686 | 0.88 | CHRNA7 (0.62) | NOTUMCHRNA7ALDH1A1OPRL1CNR1 | |
| SCHEMBL4492901 | 0.84 | MAPK1 (0.67) | CHRNA7ALDH1A1OPRL1CNR1CNR2 | |
| SCHEMBL5922302 | 0.83 | MAPT (0.63) | NOTUMCHRNA7ALDH1A1OPRL1CNR1 | |
| SCHEMBL16403258 | 0.83 | NOTUM (0.70) | NOTUMCHRNA7ALDH1A1 | |
| SCHEMBL14270597 | 0.83 | CNR1 (0.56) | NOTUMCHRNA7CNR1 | |
| SCHEMBL5922354 | 0.82 | CHRNA7 (0.61) | CHRNA7OPRL1CNR1CNR2SMN1; SMN2 | |
| SCHEMBL1988812 | 0.82 | CHRNA7 (0.47) | NOTUMCHRNA7ALDH1A1OPRL1CNR1 | |
| SCHEMBL5922325 | 0.81 | NOTUM (0.67) | NOTUMCHRNA7ALDH1A1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122230-A1 | 1,5-Diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | claimed |
| US-7524971-B2 | 1,5-diarylpyrrole derivatives, preparation method thereof and application of same in therapeutics | SANOFI - AVENTIS (FR) | 2009-04-28 | — | — | US | disclosed |
| US-20080015245-A1 | 1,5-DIARYLPYRROLE DERIVATIVES, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-01-17 | — | — | US | disclosed |
| EP-1853557-A2 | 1,5-DIARYLPYRROLE DERIVATIVES, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2007-11-14 | — | — | EP | disclosed |
| US-20060198893-A1 | Aqueous dispersion comprising stable nanoparticles of a water-insoluble pyrrole carboxamide and excipient like middle chain triglycerides | ASTRAZENECA AB (SE) | 2006-09-07 | — | — | US | disclosed |
| WO-2006087476-A2 | 1,5-DIARYLPYRROLE DERIVATIVES, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2006-08-24 | — | — | WO | disclosed |
| US-20060122230-A1 | 1,5-Diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
| EP-1592404-A1 | AQUEOUS DISPERSION COMPRISING STABLE NANOPARTICLES OF A WATER-INSOLUBLE PYRROLE CARBOXAMIDE AND AN EXCIPIENT LIKE MIDDLE CHAIN TRIGLYCERIDES | AstraZeneca AB (SE) | 2005-11-09 | — | — | EP | disclosed |
| EP-1578417-A1 | 1,5-DIARYL-PYRROLE-3-CARBOXAMIDE DERIVATIVES AND THEIR USE AS CANNABINOID RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004069227-A1 | AQUEOUS DISPERSION COMPRISING STABLE NANOPARTICLES OF A WATER-INSOLUBLE PYRROLE CARBOXAMIDE AND EXCIPIENT LIKE MIDDLE CHAIN TRIGLYCERIDES | ASTRAZENECA AB (SE) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004058249-A1 | 1,5-DIARYL-PYRROLE-3-CARBOXAMIDE DERIVATIVES AND THEIR USE AS CANNABINOID RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015245-A1 | 1,5-DIARYLPYRROLE DERIVATIVES, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | QDPR, DPYD, CD38 | NOTUM 1296/4885CHRNA7 3779/4885ALDH1A1 100/4885 |
| US-20060198893-A1 | Aqueous dispersion comprising stable nanoparticles of a water-insoluble pyrrole carboxamide and excipient like middle chain triglycerides | CETP, PNLIP, LIPC | NOTUM 19/4885CHRNA7 4278/4885ALDH1A1 1550/4885 |
| US-20060122230-A1 | 1,5-Diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | NOTUM 2381/4885CHRNA7 146/4885ALDH1A1 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.